LY6E

Across TCGA pan-cancer cohorts, LY6E mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LY6E’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where LY6E mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LY6E is over-expressed in tumor.

HNSC, LUAD, and PDAC are the cancer types where LY6E tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LY6E mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.167	<.001	11	view →
LUAD	Female	All	+0.910	<.001	8	view →
PDAC	Female	II,III,IV	+1.813	<.001	7	view →
LSCC	Male	All	+0.288	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

LY6E–HNSC

Open the HNSC breakdown →